Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 0.78 |
| ▸ | HTR1D | P28221 | 11/20 | 0.74 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | HTR1B | P28222 | 7/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.65 |
| ▸ | HTR3B | O95264 | 3/20 | 0.65 |
| ▸ | HTR1E | P28566 | 3/20 | 0.65 |
| ▸ | HTR1F | P30939 | 3/20 | 0.65 |
| ▸ | HTR7 | P34969 | 3/20 | 0.65 |
| ▸ | HTR3A | P46098 | 3/20 | 0.65 |
| ▸ | HTR5A | P47898 | 3/20 | 0.65 |
| ▸ | HTR6 | P50406 | 3/20 | 0.65 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bufotenine SCHEMBL29353068 | 1.00 | HTR2C (1.00) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| Bufotenine SCHEMBL5832731 | 0.93 | HTR1A (0.86) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL31041081 | 0.88 | HTR2C (1.00) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL21846788 | 0.87 | HTR1D (0.77) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL23069145 | 0.85 | HTR1D (0.78) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL21333441 | 0.85 | HTR2C (0.74) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| Bufotenine SCHEMBL31098272 | 0.85 | HTR2C (0.74) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL23069123 | 0.85 | HTR1D (1.00) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL23069161 | 0.84 | HTR2C (0.72) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL8891077 | 0.84 | HTR1D (1.00) | HTR2CHTR1AHTR2ASLC6A4HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595497-B2 | Processes for the production of tryptamines | COMPASS PATHFINDER LIMITED (GB) | 2026-04-07 | — | — | US | claimed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-12514883-B2 | Compositions and methods for modulating lipid and steroid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| US-20250375420-A1 | COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN | ZYLORION HEALTH INC (CA) | 2025-12-11 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| US-12472163-B2 | Compositions of matter and pharmaceutical compositions | ATAI THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2025-09-11 | — | — | US | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| WO-2002024865-A2 | MODULATION OF SECONDARY METABOLITE PRODUCTION BY ZINC BINUCLEAR CLUSTER PROTEINS | MICROBIA, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001054681-A2 | COMPOSITION FOR TREATMENT OF STRESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-08-02 | — | — | WO | claimed |
| EP-1096927-A1 | COMPOSITION FOR TREATMENT OF STRESS | Massachusetts Institute of Technology (US) | 2001-05-09 | — | — | EP | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000003701-A1 | COMPOSITION FOR TREATMENT OF STRESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-27 | — | — | WO | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | VDR, OPRD1, HTR1A | HTR2C 14/4885HTR1A 3/4885HTR2A 11/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2C 42/4885HTR1A 9/4885HTR2A 14/4885 |
| US-12472163-B2 | Compositions of matter and pharmaceutical compositions | TPH1, HTR1B, HTR2C | HTR2C 3/4885HTR1A 8/4885HTR2A 7/4885 |
| US-12595497-B2 | Processes for the production of tryptamines | INMT, TPH1, TPH2 | HTR2C 38/4885HTR1A 59/4885HTR2A 67/4885 |
| US-20250375420-A1 | COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN | BDNF, NGF, PYGB | HTR2C 41/4885HTR1A 75/4885HTR2A 28/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2C 5/4885HTR1A 4/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.